论文部分内容阅读
目的观察卡维地洛治疗缺血性心脏病心力衰竭及对QT离散度(QTD)和恶性室性心律失常发生的影响。方法62例缺血性心脏病心力衰竭患者随机分成卡维地洛治疗组和常规治疗组(每组31例)。监测治疗前及治疗6个月后6min步行距离,每搏输出量(SV)及每分心输出量(CO);超声心动图监测左室射血分数(EF)、左室舒张末期内径(LEVDD)及左室收缩末期内径(LVESD),同时监测心功能、收缩压、舒张压及心率的变化;QTd及恶性室性心律失常。结果治疗6个月后,两组心功能均未明显改善。卡维地洛组6min步行距离较常规治疗组明显改善;射血分数(EF)、每搏输出量(SV)及每分心输出量(CO)较常规治疗组明显增加;左室舒张末期内径(LEVDD)及左室收缩末期内径(LVESD)较常规治疗组明显降低;收缩压、舒张压、心率及QTd较常规治疗组明显降低;恶性室性心律失常检出率明显降低。结论卡维地洛能显著改善缺血性心脏病心力衰竭,改善左室重塑,使QTd缩短而减少恶性室性心律失常的发生。
Objective To observe the effects of carvedilol on heart failure in patients with ischemic heart disease (QTD) and malignant ventricular arrhythmias (QTD). Methods Sixty-two patients with ischemic heart disease and heart failure were randomly divided into carvedilol treatment group and conventional treatment group (31 cases in each group). The 6-minute walking distance, stroke volume (SV) and per unit cardiac output (CO) were measured before and 6 months after treatment. The left ventricular ejection fraction (EF), left ventricular end diastolic diameter (LEVDD ) And left ventricular end-systolic diameter (LVESD). Meanwhile, heart function, systolic blood pressure, diastolic blood pressure and heart rate were monitored. QTd and malignant ventricular arrhythmias were also observed. Results After 6 months of treatment, no significant improvement was found in both groups. Carvedilol group 6min walking distance than the conventional treatment group significantly improved; ejection fraction (EF), stroke volume (SV) and per cardiac output (CO) was significantly increased compared with conventional treatment group; left ventricular end-diastolic diameter (LEVDD) and left ventricular end systolic diameter (LVESD) were significantly lower than those in the conventional treatment group. Systolic blood pressure, diastolic blood pressure, heart rate and QTd were significantly lower than those in the conventional treatment group. The detection rate of malignant ventricular arrhythmia was significantly lower. Conclusion Carvedilol can significantly improve heart failure of ischemic heart disease, improve left ventricular remodeling, shorten QTd and reduce the incidence of malignant ventricular arrhythmia.